This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 24/4/762    most recent 01.ATV.0000122363.02961.c1v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wooton-Kee, C. R. Articles by Webb, N. R. Search for Related Content PubMed PubMed Citation Articles by Wooton-Kee, C. R. Articles by Webb, N. R. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Related Collections Genetically altered mice Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:762.)
© 2004 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Group V sPLA₂ Hydrolysis of Low-Density Lipoprotein Results in Spontaneous Particle Aggregation and Promotes Macrophage Foam Cell Formation

C. Ruth Wooton-Kee; Boris B. Boyanovsky; Munira S. Nasser; Willem J.S. de Villiers; Nancy R. Webb

From the Department of Internal Medicine, University of Kentucky Medical Center, Lexington, Kentucky.

Correspondence to Dr N. R. Webb, Department of Internal Medicine, University of Kentucky Medical Center MN520, 800 Rose Street, Lexington, KY 40536-0084. E-mail nrwebb1{at}uky.edu

Objectives— Secretory phospholipase A₂ (sPLA₂) enzymes hydrolyze the sn-2 fatty acyl ester bond of phospholipids to produce a free fatty acid and a lysophospholid. Group V sPLA₂ is expressed in cultured macrophage cells and has high affinity for phosphatidyl choline-containing substrates. The present study assesses the presence of group V sPLA₂ in human and mouse atherosclerotic lesions and its activity toward low-density lipoprotein (LDL) particles.

Methods and Results— Group V sPLA₂ was detected in human and mouse atherosclerotic lesions by immunohistochemical staining. Electron microscopic analysis showed that mouse group V sPLA₂-modified LDL is significantly smaller (mean diameter±SEM=25.3±0.25 nm) than native LDL (mean diameter±SEM=27.7±0.29 nm). Hydrolysis by group V sPLA₂ induced spontaneous particle aggregation; the extent of aggregation was directly proportional to the degree of LDL hydrolysis. Group V sPLA₂ modification of LDL led to enhanced lipid accumulation in cultured mouse peritoneal macrophage cells.

Conclusions— Group V sPLA₂ may play an important role in promoting atherosclerotic lesion development by modifying LDL particles in the arterial wall, thereby enhancing particle aggregation, retention, and macrophage uptake.

Key Words: atherosclerosis • group V secretory phospholipase A₂ • LDL aggregation • macrophages

This article has been cited by other articles:

				Z. Shaposhnik, X. Wang, J. Trias, H. Fraser, and A. J. Lusis The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002) J. Lipid Res., April 1, 2009; 50(4): 623 - 629. [Abstract] [Full Text] [PDF]

				B. B. Boyanovsky, P. Shridas, M. Simons, D. R. van der Westhuyzen, and N. R. Webb Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL J. Lipid Res., April 1, 2009; 50(4): 641 - 650. [Abstract] [Full Text] [PDF]

				B. Boyanovsky, M. Zack, K. Forrest, and N. R. Webb The Capacity of Group V sPLA2 to Increase Atherogenicity of ApoE-/- and LDLR-/- Mouse LDL In Vitro Predicts its Atherogenic Role In Vivo Arterioscler Thromb Vasc Biol, April 1, 2009; 29(4): 532 - 538. [Abstract] [Full Text] [PDF]

				J. J. Manning-Tobin, K. J. Moore, T. A. Seimon, S. A. Bell, M. Sharuk, J. I. Alvarez-Leite, M. P.J. de Winther, I. Tabas, and M. W. Freeman Loss of SR-A and CD36 Activity Reduces Atherosclerotic Lesion Complexity Without Abrogating Foam Cell Formation in Hyperlipidemic Mice Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 19 - 26. [Abstract] [Full Text] [PDF]

				H. Sato, R. Kato, Y. Isogai, G.-i. Saka, M. Ohtsuki, Y. Taketomi, K. Yamamoto, K. Tsutsumi, J. Yamada, S. Masuda, et al. Analyses of Group III Secreted Phospholipase A2 Transgenic Mice Reveal Potential Participation of This Enzyme in Plasma Lipoprotein Modification, Macrophage Foam Cell Formation, and Atherosclerosis J. Biol. Chem., November 28, 2008; 283(48): 33483 - 33497. [Abstract] [Full Text] [PDF]

				K. Oorni and P. T. Kovanen PLA2-V: A Real Player in Atherogenesis Arterioscler Thromb Vasc Biol, March 1, 2007; 27(3): 445 - 447. [Full Text] [PDF]

				M. A. Bostrom, B. B. Boyanovsky, C. T. Jordan, M. P. Wadsworth, D. J. Taatjes, F. C. de Beer, and N. R. Webb Group V Secretory Phospholipase A2 Promotes Atherosclerosis: Evidence From Genetically Altered Mice Arterioscler Thromb Vasc Biol, March 1, 2007; 27(3): 600 - 606. [Abstract] [Full Text] [PDF]

				S.-A. Karabina, I. Brocheriou, G. Le Naour, M. Agrapart, H. Durand, M. Gelb, G. Lambeau, and E. Ninio Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function FASEB J, December 1, 2006; 20(14): 2547 - 2549. [Abstract] [Full Text] [PDF]

				D. Namgaladze and B. Brune Phospholipase A2-Modified Low-Density Lipoprotein Activates the Phosphatidylinositol 3-Kinase-Akt Pathway and Increases Cell Survival in Monocytic Cells Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2510 - 2516. [Abstract] [Full Text] [PDF]

				B. Rosengren, H. Peilot, M. Umaerus, A.-C. Jonsson-Rylander, L. Mattsson-Hulten, C. Hallberg, P. Cronet, M. Rodriguez-Lee, and E. Hurt-Camejo Secretory Phospholipase A2 Group V: Lesion Distribution, Activation by Arterial Proteoglycans, and Induction in Aorta by a Western Diet Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1579 - 1585. [Abstract] [Full Text] [PDF]

				M. Sneck, P. T. Kovanen, and K. Oorni Decrease in pH Strongly Enhances Binding of Native, Proteolyzed, Lipolyzed, and Oxidized Low Density Lipoprotein Particles to Human Aortic Proteoglycans J. Biol. Chem., November 11, 2005; 280(45): 37449 - 37454. [Abstract] [Full Text] [PDF]

				U. A. Kessen, R. H. Schaloske, D. L. Stephens, K. Killermann Lucas, and E. A. Dennis PGE2 release is independent of upregulation of Group V phospholipase A2 during long-term stimulation of P388D1 cells with LPS J. Lipid Res., November 1, 2005; 46(11): 2488 - 2496. [Abstract] [Full Text] [PDF]

				B. B. Boyanovsky, D. R. van der Westhuyzen, and N. R. Webb Group V Secretory Phospholipase A2-modified Low Density Lipoprotein Promotes Foam Cell Formation by a SR-A- and CD36-independent Process That Involves Cellular Proteoglycans J. Biol. Chem., September 23, 2005; 280(38): 32746 - 32752. [Abstract] [Full Text] [PDF]

				K. Oorni, P. Posio, M. Ala-Korpela, M. Jauhiainen, and P. T. Kovanen Sphingomyelinase Induces Aggregation and Fusion of Small Very Low-Density Lipoprotein and Intermediate-Density Lipoprotein Particles and Increases Their Retention to Human Arterial Proteoglycans Arterioscler Thromb Vasc Biol, August 1, 2005; 25(8): 1678 - 1683. [Abstract] [Full Text] [PDF]

				S. A. I. Ghesquiere, M. J. J. Gijbels, M. Anthonsen, P. J. J. van Gorp, I. van der Made, B. Johansen, M. H. Hofker, and M. P. J. de Winther Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition J. Lipid Res., February 1, 2005; 46(2): 201 - 210. [Abstract] [Full Text] [PDF]